The incremental value of the contribution of a biostatistician to the reporting quality in health research - a retrospective, single center, observational cohort study

Abstract:
Background The reporting quality in medical research has recently been critically discussed. While reporting guidelines intend to maximize the value from funded research, and initiatives such as the EQUATOR network have been introduced to advance high quality reporting, the uptake of the guidelines by researchers could be improved. The aim of this study was to assess and quantify the contribution of a biostatistician to the reporting and methodological quality of health research, and to identify methodological knowledge gaps.

Methods In a retrospective, single center, observational cohort study, two groups of publications were compared. The group of exposed publications had an academic biostatistician on the author list, whereas the group of non-exposed publications did not include a biostatistician of the evaluated group. Rating of reporting quality was done in blinded fashion and in duplicate. The primary outcome was a sum score based on six dimensions, ranging between 0 (worst) and 11 (best). The study protocol was reviewed and approved as a registered report.

Results There were 131 publications in the exposed group published between 2017 and 2018. Of these, 95 were either RCTs, observational, or prediction / prognostic studies. Corresponding matches in the group of non-exposed publications were identified in a reproducible manner. Comparison of reporting quality overall revealed a 1.6 (95%CI from 0.92 to 2.28, p <0.0001) units higher reporting quality for exposed publications. A subgroup analysis within study types showed higher reporting quality across all three study types.

Conclusion Our study is the first to demonstrate a higher reporting quality and methodological strength in health research publications with a biostatistician on the author list. The higher reporting quality persisted through subgroups of study types and dimensions. Methodological knowledge gaps were identified for prediction / prognostic studies, and for reporting on statistical methods in general and missing values, specifically.
### Additional Information:

#### Question

**Financial Disclosure**

Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the [submission guidelines](#) for detailed requirements. View published research articles from [PLOS ONE](#) for specific examples.

This statement is required for submission and will appear in the published article if the submission is accepted. Please make sure it is accurate.

**Unfunded studies**

Enter: *The author(s) received no specific funding for this work.*

**Funded studies**

Enter a statement with the following details:

- Initials of the authors who received each award
- Grant numbers awarded to each author
- The full name of each funder
- URL of each funder website
- Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript?
  
  - **NO** - Include this sentence at the end of your statement: *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*
  
  - **YES** - Specify the role(s) played.

* typeset

#### Response

The study was supported by the Center for Reproducible Science at the University of Zurich (https://www.crs.uzh.ch/en.html). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### Competing Interests

Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors, disclose any competing interests that could be perceived to bias this

I have read the journal's policy and SL has the following competing interests: SL is employed by CTU Bern, University of Bern, which has a staff policy of not accepting honoraria or consultancy fees. However, CTU Bern is involved in design, conduct, or analysis of clinical studies funded by not-for-profit and for-profit organizations. In particular, pharmaceutical and medical device companies provide direct funding to some of these studies. For an up-to-date list of CTU Bern’s conflicts of interest: [http://www.ctu.unibe.ch/research/declaration of interest/index eng.html](http://www.ctu.unibe.ch/research/declaration of interest/index eng.html).
work—acknowledging all financial support and any other relevant financial or non-financial competing interests.

This statement is required for submission and will appear in the published article if the submission is accepted. Please make sure it is accurate and that any funding sources listed in your Funding Information later in the submission form are also declared in your Financial Disclosure statement.

View published research articles from *PLOS ONE* for specific examples.

| NO authors have competing interests |
|-------------------------------------|
| Enter: *The authors have declared that no competing interests exist.* |

| Authors with competing interests |
|----------------------------------|
| Enter competing interest details beginning with this statement: |

*I have read the journal’s policy and the authors of this manuscript have the following competing interests: [insert competing interests here]*

* typeset

| Ethics Statement |
|------------------|
| Enter an ethics statement for this submission. This statement is required if the study involved: |

- Human participants
- Human specimens or tissue
- Vertebrate animals or cephalopods
- Vertebrate embryos or tissues
- Field research

Write "N/A" if the submission does not require an ethics statement.

| N/A |

UH, KS, MH, VLC, AG, SH, EAW, MG, KAR, SVF, and EF declare to have no conflict of interest.
General guidance is provided below. Consult the submission guidelines for detailed instructions. **Make sure that all information entered here is included in the Methods section of the manuscript.**

### Format for specific study types

#### Human Subject Research (involving human participants and/or tissue)
- Give the name of the institutional review board or ethics committee that approved the study
- Include the approval number and/or a statement indicating approval of this research
- Indicate the form of consent obtained (written/oral) or the reason that consent was not obtained (e.g. the data were analyzed anonymously)

#### Animal Research (involving vertebrate animals, embryos or tissues)
- Provide the name of the Institutional Animal Care and Use Committee (IACUC) or other relevant ethics board that reviewed the study protocol, and indicate whether they approved this research or granted a formal waiver of ethical approval
- Include an approval number if one was obtained
- If the study involved non-human primates, add additional details about animal welfare and steps taken to ameliorate suffering
- If anesthesia, euthanasia, or any kind of animal sacrifice is part of the study, include briefly which substances and/or methods were applied

#### Field Research
Include the following details if this study involves the collection of plant, animal, or other materials from a natural setting:
- Field permit number
- Name of the institution or relevant body that granted permission

### Data Availability
Authors are required to make all data underlying the findings described fully

| | Yes - all data are fully available without restriction |
available, without restriction, and from the
time of publication. PLOS allows rare
exceptions to address legal and ethical
concerns. See the PLOS Data Policy and
FAQ for detailed information.

A Data Availability Statement describing
where the data can be found is required at
submission. Your answers to this question
constitute the Data Availability Statement
and will be published in the article, if
accepted.

**Important:** Stating ‘data available on request
from the author’ is not sufficient. If your data
are only available upon request, select ‘No’ for
the first question and explain your exceptional
situation in the text box.

Do the authors confirm that all data
underlying the findings described in their
manuscript are fully available without
restriction?

Describe where the data may be found in
full sentences. If you are copying our
sample text, replace any instances of **XXX**
with the appropriate details.

- If the data are **held or will be held in a
  public repository**, include URLs,
  accession numbers or DOIs. If this
  information will only be available after
  acceptance, indicate this by ticking the
  box below. For example: *All **XXX** files
  are available from the **XXX** database
  (accession number(s) **XXX**, **XXX**).
- If the data are all contained **within the
  manuscript and/or Supporting
  Information files**, enter the following:
  *All relevant data are within the
  manuscript and its Supporting
  Information files.*
- If neither of these applies but you are
  able to provide **details of access
  elsewhere**, with or without limitations,
  please do so. For example:

  *Data cannot be shared publicly because
  of [**XXX**]. Data are available from the
  **XXX** Institutional Data Access / Ethics

The data underlying the results presented in the study are available on OSF
(https://osf.io/5egrn/).
Committee (contact via XXX) for researchers who meet the criteria for access to confidential data.

The data underlying the results presented in the study are available from (include the name of the third party and contact information or URL).

- This text is appropriate if the data are owned by a third party and authors do not have permission to share the data.

* typeset

Additional data availability information:
The incremental value of the contribution of a biostatistician to the reporting quality in health research - a retrospective, single center, observational cohort study

Ulrike Held1*, Klaus Steigmiller1, Michael Hediger2, Victoria L. Cammann3, Alexandru Garaiman4, Sascha Halvachizadeh5, Sylvain Losdat6, Erin Ashley West7, Martina Gosteli8, Kelly A. Reeve1, Stefanie von Felten1, Eva Furrer1

1 Department of Biostatistics at Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland
2 Institute of Mathematics, University of Zurich, Switzerland
3 University Heart Center, Department of Cardiology, University Hospital Zurich, University of Zurich, Switzerland
4 Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland
5 Department of Trauma, University Hospital Zurich, University of Zurich, Switzerland
6 CTU Bern, University of Bern, Switzerland
7 Department of Epidemiology at Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland
8 Main Library, University of Zurich, Switzerland

*These authors contributed equally to this work.

Abstract

**Background:** The reporting quality in medical research has recently been critically discussed. While reporting guidelines intend to maximize the value from funded research, and initiatives such as the EQUATOR network have been introduced to advance high quality reporting, the uptake of the guidelines by researchers could be improved. The aim of this study was to assess and quantify the contribution of a biostatistician to the reporting and methodological quality of health research, and to identify methodological knowledge gaps.

**Methods:** In a retrospective, single center, observational cohort study, two groups of publications were compared. The group of exposed publications had an academic biostatistician on the author list, whereas the group of non-exposed publications did not include a biostatistician of the evaluated group. Rating of reporting quality was done in blinded fashion and in duplicate. The primary outcome was a sum score based on six dimensions, ranging between 0 (worst) and 11 (best). The study protocol was reviewed and approved as a registered report.

**Results:** There were 131 publications in the exposed group published between 2017 and 2018. Of these, 95 were either RCTs, observational, or prediction / prognostic studies. Corresponding matches in the group of non-exposed publications were
identified in a reproducible manner. Comparison of reporting quality overall revealed a 1.60 (95%CI from 0.92 to 2.28, p < 0.0001) units higher reporting quality for exposed publications. A subgroup analysis within study types showed higher reporting quality across all three study types.

**Conclusion:** Our study is the first to demonstrate a higher reporting quality and methodological strength in health research publications with a biostatistician on the author list. The higher reporting quality persisted through subgroups of study types and dimensions. Methodological knowledge gaps were identified for prediction / prognostic studies, and for reporting on statistical methods in general and missing values, specifically.

**Introduction**

Despite measures to increase the reporting quality in the field of health research, for example, by introducing reporting guidelines and inclusion of such guidelines in recommendations for authors by many publishers, quality standards are still oftentimes not met. Recent evaluations of the literature showed that for observational studies, the corresponding STROBE guideline was not used by nearly 18% of the authors because the authors had not heard of the guideline before. An additional 19% of authors had heard of it but still did not use it [1]. Journals obviously play an important role, and a systematic evaluation showed that journal endorsement rates to the STROBE guidelines are only around 50% [2]. When it comes to the reporting of randomized trials, Dechartres et al. [3] have systematically evaluated reporting of more than 20'000 trials included in Cochrane reviews. They conclude that poor reporting has decreased over time, but that especially lower impact factor journals show room for improvement.

Reporting quality of clinical prediction models has recently been evaluated systematically in the context of research on Severe acute respiratory syndrome coronavirus 2 (Sars-Cov-2) [4]. The authors concluded that almost all published models for predicting mortality were poorly reported, and that the corresponding Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD [5]) guideline was largely omitted.

In Switzerland, the government paid 22.9 billion Swiss francs for research and development, representing more than 3% of the gross domestic product in 2019. Publications in the field of “clinical medicine” represent 25% of all publications [6], and given the large amounts of resources, value from research and publications should be maximized.

The objectives of the current study were, first, to quantify the contribution of a biostatistician as co-author on the quality of reporting and methodological strength in health research publications; second, to identify dimensions of reporting quality and study types with methodological knowledge gaps; and third, to promote the awareness of the importance of good reporting among clinical researchers and biostatisticians.

**Materials and methods**

**Study design**

The study is a retrospective, single-center observational cohort study, conducted at the University of Zurich (UZH) and its University Hospital (USZ).
Selection of exposed and non-exposed publications

In this study, two groups of publications were compared. The group of "exposed" publications was defined according to their exposure to one or more of a set of 13 academic biostatisticians from the Epidemiology, Biostatistics and Prevention Institute, and the Institute of Mathematics, both localized at University of Zurich, as a co-author. The group will be referred to as biostatisticians in the following. The group of exposed publications was published between 2017 and 2018, and it was retrieved in a PubMed search, with a search string as specified in S1 Appendix on Dec 9, 2019. Methodological publications as well as non-English language publications were excluded.

To define the group of "non-exposed" publications for comparison, all medical research publications found in PubMed between 2017 and 2018, with the affiliation UZH or USZ or any of the affiliated university hospitals for the first and/or the second author were extracted on Dec 16, 2019. Details on the search string can again be found in S1 Appendix. The non-exposed publications have none of the defined set of biostatisticians on the author list. It cannot be excluded that a biostatistician from outside of the group was on the author list. The full list of affiliations considered can be found in S2 Appendix. Based on the full list, a list of affiliations relevant for this study was created, in which for example typographic errors were removed. The large number of non-exposed publications resulting from the affiliation list was used in a random but replicable order - aiming to remove potential chronological ordering or any other systematic ordering while adhering to high standards of reproducibility.

Categorization into study types

For each of the exposed publications, the study type was determined, and the subset of all RCTs, observational studies, and prediction/prognostic studies was evaluated further. Categorization into study types was performed by the set of biostatisticians. For most publications, the authors themselves determined the study type. For some publications, the biostatistician as co-author had left the department, and thus the study type was categorized independently and in duplicate by two authors (UH, EF). After consensus on study type was reached, record count for each study type for each publication year was obtained. The three study types RCT, observational study, and prediction/prognostic study were the most frequent types. Other types (e.g. systematic reviews) had been abandoned a priori.

The number of non-exposed publications was much larger than the number of exposed publications. For that reason, the categorization of the non-exposed publications into RCTs, observational studies and prediction/prognostic studies was performed in random but replicable order until the numbers of non-exposed publications of these study types matched the corresponding number of exposed publications per year. Categorization was performed independently and in duplicate by the authors UH and MH (for papers published in 2017) and by EF and MH (for 2018). Any discrepancies were resolved by discussion and third-party arbitration (KS). The final set of publications was considered the non-exposed group of publications.

Selection of items from reporting guideline

For each study type, a set of six items measuring reporting quality were identified by reaching group consensus among the set of biostatisticians. The quality criteria were based on the reporting guidelines CONSORT [7], STROBE, and TRIPOD, and they reflect characteristics of a publication that are especially important for judging the validity of the results and methodological strength.
Specification of the reporting quality items

The reporting guideline items chosen for the ratings represented the following general dimensions for all three study types: 1. variable specification; 2. how study size was arrived at; 3. missing data; 4. statistical methods; 5. precision of results; and 6. whether the corresponding reporting guideline was mentioned.

The rating of publications regarding these six items was operationalized and piloted, such that they could be used efficiently and robustly to rate each publication consistently. Each dimension had different possible answer categories, also dependent on study type, resulting in a rating varying between 0 (lowest) to 2 (highest) for dimensions 1 to 5, plus an additional point for mentioning the corresponding reporting guideline. Details of the operationalization can be found in S3 Appendix. The range of the total score was from 0 (lowest) to 11 (highest).

Outcomes

The primary outcome of this study was the sum score of reporting quality and methodological strength in exposed and non-exposed publications, with respect to the six dimensions. The primary outcome was assessed in blinded fashion and in duplicate by two independent raters. The raters were recruited from outside of the departments. Blinding to whether the publication belonged to the exposed or non-exposed group was guaranteed by removing author names, affiliation lists, journal name, corresponding author name, author contributions, date, acknowledgements, references, and DOI from every publication’s PDF. Discrepancies in the ratings between the two raters were resolved by a third rating and discussion until consensus was reached.

The secondary outcome of this study was the number of citations in the group of exposed and non-exposed publications at a fixed date (July 20, 2021).

Outcome rating and rater training

The outcome rating and its operationalization was developed by four authors (UH, KS, MH, EF). After operationalization was finalized the resulting questions for each study type were programmed to be evaluated through an R Shiny app, which underwent quality review and a testing period. The questionnaire can be found in S3 Appendix. To find raters, outside of the core study team and outside of the departments, PhD programs in health research across Switzerland, as well as groups of researchers interested in Research on Research were contacted. Each candidate rater could choose a study type, and received written instructions for the rating task. The candidate raters were instructed and trained by rating vignette publications for calibration. These vignette publications of all study types were similar publications as those under study, but they were published in 2019 and were rated with scrutiny by the study authors, including detailed explanation. Only upon successful completion of test ratings, the raters received sets of 11-12 papers of the same study type for rating. The raters were obliged to rate the reporting quality based on the blinded PDF’s alone, and not to use additional information from the internet while doing so. Ratings were performed in blinded fashion, meaning that the raters were unaware of the classification of publications as exposed or non-exposed, and of authors on the publications. The ratings were performed in duplicate, and any discrepancies were resolved by a third independent rating. The raters were reimbursed with vouchers for every set of 11-12 publications. Additionally, raters were asked for co-authorship after completion of 33 or more ratings. In total, 15 raters were recruited. The ratings were done between May and July 2021.
Sample size considerations

The sample size was justified a priori, based on the consideration that with 95 publications in the exposed group, and 95 publications in the non-exposed group at a significance level of 5% and with a power of 80% an effect size of 0.41 (Cohen’s $d$) could be detected, using a 2-sided, 2-sample t-test with equal variance assumption. The effect size would be considered a medium effect size. The number of 95 publications corresponded to all publications in the exposed group in the years 2017 and 2018.

Data management

Data collection in the context of this study had to cover two different aspects. First, categorization of the exposed and non-exposed publications into the three study types was performed with the help of a specifically programmed R Shiny app, in which the title and abstract, as well as the link to the full text was provided, such that the categorization could be performed independently and in duplicate and that any discrepancies could be detected and resolved by discussion. Second, reporting quality rating was performed using another R Shiny app, implementing the operationalized quality dimensions. The electronic records of the two independent ratings, and the consensus rating were saved. The use of R Shiny apps in this research guaranteed highly reliable data entry.

Risk of bias

The study was designed to compensate the following biases a priori. Risk of detection bias was addressed with blinded and duplicate outcome ratings by researchers not otherwise involved in the study. Risk of selection bias was addressed with reproducible random sub sampling of PubMed publications from medical publications with UZH / USZ affiliation for the group of non-exposed publications. The results of the study could be confounded by indication, if more complex research projects were brought to the group of biostatisticians’ attention whereas less complex projects were addressed by the clinicians without asking for help from an academic biostatistician. This bias was partially addressed by comparing the number of citations of exposed and non-exposed publications, under the hypothesis that equal citation numbers would indicate that less confounding by indication was present.

Statistical methods and programming

For assessing the level of agreement of reporting quality between the two independent ratings, squared-weighted Cohen’s $\kappa$ values were estimated, and reported with 95% confidence intervals based on 1000 bootstrap samples. These analyses of agreement were reported overall and in subgroups of study type. Interpretation of the $\kappa$ values were based on the categorization suggested by Altman [8].

Statistical methods for the primary outcome included visualization of the results with dot-plots (lollipop plots), in which the means of the outcome in the exposed and non-exposed publications are shown, overall (score 0 to 11), and in subgroups of study type (score 0 to 11) and reporting quality dimension (score 0 to 2). Besides that, the estimated between-group differences, overall and in subgroups of study type with 95% confidence intervals (CI) were reported. The two-sided, two-sample t-test under the assumption of equal variances was used to test the hypothesis of no difference in reporting quality between exposed and non-exposed publications. Corresponding Cohen’s $d$ was calculated using pooled standard deviations assuming equal variances.
The number of citations was reported overall, and in subgroups of study type, with medians and interquartile ranges, as the distribution was right-skewed. The non-parametric exact Wilcoxon-Mann-Whitney method was used to test the hypothesis of no difference in number of citations between exposed and non-exposed publications, and to estimate a confidence interval. The between-group difference in location was estimated and reported with 95% CI, based on rank statistics.

All analyses, including subgroup analyses described above were pre-specified in the registered report study protocol [9]. The unit of analysis was the individual publication, or the reporting quality dimension.

Statistical programming was performed with R 4.1.1 [10], in combination with dynamic reporting. Statistical programming included downloading all potential non-exposed publications, random reordering, development of an R Shiny app for categorization of the publications, development of an R Shiny app for the recording of reporting quality ratings, as well as statistical programming of the methods for data analysis and visualization. Results of the study were reported according to STROBE guidelines [11]. All anonymized data was uploaded in an OSF repository.

## Results

In total there were 131 exposed papers published in 2017 and 2018. Of these, 95 publications were of the study types RCT, observational study, or prediction / prognostic study. There were six RCTs, 77 observational studies, and 12 prediction / prognostic studies. The literature search for non-exposed publications with first and / or second author with suitable affiliation and year resulted in a total number of 3420 publications. Four hundred publications of these in random order were categorized into one of the three study types RCT, observational, or prediction / prognostic study, and the retrieved case numbers of the exposed papers could be frequency matched individually for 2017 and 2018. The corresponding flow-chart is shown in Fig. 1. All data was made available on OSF [12].

Ten of the exposed publications and two of the non-exposed publications mentioned the corresponding reporting guideline. In 48 of the exposed publications, and in 14 of the non-exposed publications, the programming language R was used for the statistical analysis. All descriptive results can be found in Table 1. There were no missing values in the data throughout.

### Table 1. Descriptive statistics.

|                  | Exposed | Non-exposed |
|------------------|---------|-------------|
| n                | 95      | 95          |
| Study type (%)   |         |             |
| Randomized Studies | 6 (6.3) | 6 (6.3)     |
| Observational Studies | 77 (81.1) | 77 (81.1) |
| Prediction Studies | 12 (12.6) | 12 (12.6) |
| Software used (%)|         |             |
| R                | 48 (50.5) | 14 (14.7)  |
| Other            | 36 (37.9) | 60 (63.2)  |
| Not mentioned    | 11 (11.6) | 21 (22.1)  |
| Year (%)         |         |             |
| 2017             | 54 (56.8) | 54 (56.8)  |
| 2018             | 41 (43.2) | 41 (43.2)  |
| Guideline = Mentioned (%) | 10 (10.5) | 2 (2.1)   |
Agreement

The agreement between the two ratings of each publication was 0.52 (95% CI from 0.46 to 0.57) overall, indicating moderate agreement, according to Altman [8]. For the three different study types, however, the agreement varied between 0.31 (95% CI from 0.05 to 0.52) for RCTs and 0.52 (95% CI from 0.46 to 0.59) and 0.53 (95% CI from 0.35 to 0.68) for observational and prediction studies, respectively. To reach consensus for all ratings with discrepancies a third blinded rater was involved.

Primary outcome

The estimated between-group difference for the primary outcome was 1.60 (95% CI from 0.92 to 2.28, p < 0.0001) in favor of the exposed publications. This result corresponds to a Cohen’s $d$ of 0.67 (95% CI from 0.38 to 0.97). In the pre-specified subgroups of study type, the estimated between group difference was 3.33 (95% CI from -0.84 to 7.51), 1.39 (95% CI from 0.68 to 2.09) and 2.08 (95% CI from 0.12 to 4.04) for randomized, observational and prediction / prognostic studies, respectively (Fig. 2), showing higher reporting quality across all study types. In addition to the estimation of the between group difference, the representation of each subgroup’s mean values shows that generally for RCTs the reporting quality was higher than for observational and prediction / prognostic studies.

Dimension-specific score values

For each of the five reporting dimensions, the between group difference was estimated. The corresponding range of values was between 0 (worst) and 2 (best). Again the results are shown in a graphical representation (Fig. 3). The dimension “Variables” had a smaller between group difference, and a higher reporting quality overall, whereas the “Missing data” and “Statistical methods” dimensions were generally reported with less detail. The mean reporting quality in the exposed publications was higher throughout, than that of the non-exposed publications.

Number of citations

The number of citations, extracted on July 20, 2021, had a non-normal, right-skewed distribution, and for that reason the non-parametric exact Wilcoxon-Mann-Whitney method was used for the estimation of the between group difference and its confidence interval. The estimate was -2 (95% CI from -4 to 0, p = 0.07) indicating weak evidence for higher citation numbers for the non-exposed publications. All descriptive statistics for number of citations can be found in Table 2. It can be seen that the number of citations was relatively balanced for observational studies and prediction / prognostic studies, whereas in the RCTs the number of citations was much larger in the non-exposed group of publications as compared to the exposed publications.

Table 2. Descriptive statistics for number of citations. Estimates show the median [IQR].

|                     | Exposed       | Non-exposed  |
|---------------------|---------------|--------------|
| Overall             | 8.0 [3.0, 14.5]| 9.0 [6.0, 18.5]|
| Randomized Studies  | 6.5 [2.0, 10.2]| 35.5 [12.8, 417.5]|
| Observational Studies| 8.0 [3.0, 15.0]| 8.0 [6.0, 17.0]|
| Prediction Studies  | 8.5 [6.0, 12.5]| 11.5 [8.0, 17.0]|

December 2, 2021
Discussion

Summary

Our study demonstrates that academic biostatisticians as co-authors have a positive impact on reporting quality and methodological strength in health research publications, overall and in subgroups of study types. In addition to that, the subgroup analyses demonstrated that there was evidence for a higher reporting quality in the exposed publications for observational studies and prediction / prognostic studies. The CONSORT statement seems to have been taken up well, because reporting quality was highest generally, for both exposed and non-exposed publications in RCTs. Citation numbers were comparable between observational and prediction / prognostic studies, but the average number of citations for RCTs was higher in the non-exposed group of publications. Generally, the number of RCTs was very low.

Methodological knowledge gaps seemed to be more prominent in the areas of statistical methods, and missing values. Nevertheless the mean reporting quality was higher in the exposed publications, throughout all subgroups. While it seems reasonable to assume that in the exposed papers the biostatisticians knew the methods well, there was still sub optimal reporting of these. The rating of reporting quality was performed in duplicate, and the agreement between first and second ratings were moderate to good, overall. The difficulties in the rating tasks were an indicator of sub optimal reporting in itself. Our study is the first to our knowledge to develop and use a rating score that is usable across study types, and which allows the comparison of reporting quality across study types. Low citation numbers of corresponding reporting guidelines in both, the group of exposed and non-exposed publications may be an indication of lack of awareness among study authors.

Results in the light of the literature

Our findings are in line with research on research studies evaluating the reporting quality of RCTs, observational studies and prediction / prognostic studies. While the development of reporting guidelines has been ongoing over the last 20 years, and the use of CONSORT is well-established for RCTs, there seem to remain areas in which good reporting less frequently observed. The Cochrane collaboration has initiated the "Prognosis Methods Group" to encourage and facilitate the systematic review and meta analysis of prognostic models in clinical research. Similar to the many systematic evaluations of research questions addressed with RCTs in Cochrane, the field of prediction / prognostic research will benefit and reporting as well as methodological quality will likely increase. Currently, there are 12 prognostic model reviews being undertaken in different fields of clinical research, of which one has been published [13].

Observational studies were the most frequent study type in the sample at hand, and reporting as well as methodological quality was only moderately higher in the exposed publications than in the non-exposed publications. Although the STROBE reporting guidelines have been published in 2004, and taken up by many journals, study authors need continuing reminders as a recent publication in JAMA Surgery by Brooke et al. showed [14].

Limitations and strengths

Our study has several limitations. The sum score to assess reporting quality and methodological strength was derived and used for the first time in the context of this study. We took multiple means to propose a consistent and valid sum score by using items from the corresponding reporting guidelines CONSORT, STROBE, and TRIPOD.
directly, and thorough piloting and testing. The sum score addressed the reporting quality in dimensions in which biostatisticians play a relatively prominent role. However, methodological strength could not be rated explicitly. In our view, the assessment of methodological quality is hampered if the reporting quality is low, making reporting assessment and improvement a first important milestone in improving the quality of health research in general. In the selection process, reporting items were chosen that would partially allow the assessment of methodological quality. For example in the dimension "Study size", post-hoc power calculations for observational studies were assigned zero points, and in "Statistical methods" for prediction / prognostic studies zero points were assigned if model performance measures like discrimination or calibration were not reported. Questions across study types addressed the question of "Missing values", and explicitly asked for methods to address them if present. Risk of bias assessment could be facilitated if reporting quality was higher generally. Another limitation of our study was the low agreement between ratings for the RCTs, which turned out to be only fair. An explanation for this could have been the small number of RCTs being rated by only two different raters. Both raters were relatively consistent in their ratings: one of them being somewhat strict, and the other one relatively lenient. The discrepancies led to the fact that many questions had to be rated by a third rater to come to a consensus.

Our study has several strengths. First of all, we had written a clear study protocol, receiving an external review as a registered report. Upon review of the protocol, the study design and operationalization could be revised and improved. Second, several measures were taken to compensate for different sources of bias, as our study was observational and retrospective. These included double ratings of reporting quality, unbiased assessment of reporting quality through blinded PDFs, and highly reliable data entry through the specifically designed R Shiny app.

Implications

Our study has several implications for future research. First of all, the study design can repeatedly be applied for future assessments of reporting quality in our group or other academic centers over time. The continuing discussions about the assessment already had an impact on the awareness of the topic among the people involved. In addition, the setup can be generalized to address other documents, e.g., systematic reviews (based on PRISMA [15]), statistical analysis plans [16], or research proposals (SPIRIT [17]).

Academic biostatisticians should take more responsibility in the review of final manuscript versions, and verify the adherence to established reporting guidelines. For reporting of statistical methods and of results with precision, there should be left enough room in the publication. More emphasis should be put on adequate methods to deal with missing values and the reporting thereof.

Conclusions

Our study is the first to demonstrate the valuable impact of a biostatistician on reporting quality and methodological strength in health research. Higher reporting quality persisted through subgroups of study types and dimensions. The operationalization of the quality assessment allows the direct comparison across study types and dimensions. Methodological knowledge gaps were identified for prediction and prognostic studies, and for the reporting on statistical methods and missing values.
Acknowledgments

We would like to thank Julia Braun, Sarah Haile, and Leonhard Held for their support in extracting relevant items from the corresponding reporting guidelines, and Tina Wänn for support in data preparation and statistical programming of the Shiny apps. We would like to thank the raters involved in our study: Mattia Branca, Victoria Lucia Cammann, Sascha Halvachizadeh, Monika Hebeisen, Brigitta Gahl, Alexandru Garaiman, Andrea Götschi, Stefanie Hayoz, Nadja Hedrich, Arnaud Künzi, Sylvain Losdat, Vera Neumeier, Kelly A. Reeve, Mari Sasaki, Céline Steger, Erin West.

Conflict of interest

UH, KS, MH, VLC, AG, SH, EAW, MG, KAR, SVF, and EF declare to have no conflict of interest. SL is employed by CTU Bern, University of Bern, which has a staff policy of not accepting honoraria or consultancy fees. However, CTU Bern is involved in design, conduct, or analysis of clinical studies funded by not-for-profit and for-profit organizations. In particular, pharmaceutical and medical device companies provide direct funding to some of these studies. For an up-to-date list of CTU Bern’s conflicts of interest: http://www.ctu.unibe.ch/research/declaration_of_interest/index_eng.html.

Funding

This study received funding from the Center for Reproducible Science of the University of Zurich, Switzerland. The funding source played no role in the study design, or analysis and interpretation of results.

References

1. Sharp MK, Bertizzolo L, Rius R, Wager E, Gómez G, Hren D. Using the STROBE statement: survey findings emphasized the role of journals in enforcing reporting guidelines. J Clin Epidemiol. 2019;116:26–35.
2. Sharp MK, Tokalić R, Gómez G, Wager E, Altman DG, Hren D. A cross-sectional bibliometric study showed suboptimal journal endorsement rates of STROBE and its extensions. J Clin Epidemiol. 2019;107:42–50.
3. Dechartres A, Trinquart L, Atal I, Moher D, Dickersin K, Boutron I, et al. Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study. BMJ. 2017;357:j2490.
4. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ. 2020;369:m1328.
5. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement. Annals of Internal Medicine. 2015;162(1):55–63. doi:10.7326/M14-0697.
6. Schweizerische Eidgenossenschaft. Forschung und Entwicklung (F+E) beim Bund — Steckbrief; 2019. Available from: https://www.bfs.admin.ch/bfs/de/home/statistiken/挥发wirtschaft/forschung-entwicklung.gnpdetail.2021-0413.html?id_af0d2f9fa931c57a073be94d3e7a9017.
7. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials. Annals of Internal Medicine. 2010;152(11):726–732. doi:10.7326/0003-4819-152-11-20100601-00232.

8. Altman D. Practical Statistics for Medical Research; 1991.

9. Held U, Steigmiller K, Hediger M, Gosteli M, Reeve KA, von Felten S, et al. Is reporting quality in medical publications associated with biostatisticians as co-authors? A registered report protocol. PLoS One. 2020;15(11):e0241897.

10. R Core Team. R: A Language and Environment for Statistical Computing; 2021. Available from: https://www.R-project.org/.

11. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Journal of Clinical Epidemiology. 2008; doi:10.1016/j.jclinepi.2007.11.008.

12. Steigmiller K, Held U, Furrer E. BIQMR Repository; 2021. Available from: https://osf.io/5egrn/.

13. Kreuzberger N, Damen JA, Trivella M, Estcourt LJ, Aldin A, Umlauff L, et al. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. Cochrane Database Syst Rev. 2020;7:CD012022.

14. Brooke BS, Ghaferi AA, Kibbe MR. Effective Use of Reporting Guidelines to Improve the Quality of Surgical Research. JAMA Surg. 2021;156(6):515–516.

15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. International Journal of Surgery. 2021;88:105906. doi:https://doi.org/10.1016/j.ijsu.2021.105906.

16. Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Doré C, et al. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA. 2017;318(23):2337–2343. doi:10.1001/jama.2017.18556.

17. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Annals of Internal Medicine. 2013;158(3):200–207. doi:10.7326/0003-4819-158-3-201302050-00583.
**Screening**

**Exposed**

**Non-exposed**

**Papers with suspected affiliation**
UZH/Univ. in first or second author
(n = 3559)

**Creation of affiliation list**

**Papers according to affiliation list**
in first or second author
(n = 3420)

**Categorization**
Randomized studies n = 6
Observational studies n = 77
Prediction / prognostic studies n = 12
Other n = 36

**Categorization**
(n = 400 to strive for case numbers)

**Studies defined as exposed**
Randomized studies = 6
Observational studies n = 77
Prediction / prognostic studies n = 12

**Studies defined as non-exposed**
Randomized studies n = 6
Observational studies n = 77
Prediction / prognostic studies n = 12
Predictor Studies

Randomized Studies

Observational Studies

Favors

Non-exposed

Exposure

Exposed

Non-exposed

Between Group Difference

Mean Score

Fig2

Click here to access/download;Figure;figgg_lolli_subgroup_study_
Click here to access/download
Supporting Information
S2 Appendix Affiliation.pdf
Click here to access/download
Supporting Information
S3 Appendix Questionnaire Clean.pdf